Proposed explanations include: Tissue retention of peptide or active metabolites Persistent activation of signaling cascades beyond peptide clearance Potential for active metabolites with prolonged tissue residence Excretion Pathways Limited data on elimination routes indicates: Likely renal excretion of peptide fragments based on molecular weight and water solubility Potential hepatic contribution to metabolite clearance No evidence of accumulation in chronic dosing studies in rats and monkeys Degradation products eliminated without evidence of toxic metabolite formation The dramatic disconnect between three-minute plasma half-life and prolonged metabolic effects remains one of the most intriguing and poorly understood aspects of AOD-9604 pharmacology, requiring further mechanistic investigation
The copper-binding nature of this peptide has generated scientific interest across multiple fields, including investigations of protein expression and biological maintenance mechanisms
Read carefully the potential side effects and cautions of the contents
Applying the peptide solution immediately after needling maximizes penetration through open channels
Over time, this can lead to inflammation, high blood pressure, poor circulation, and diseases like atherosclerosis, autoimmune disorders, infections, and organ failure
CYP4F11 is primarily expressed in liver, but also found in kidney, heart, brain and skeletal muscle